⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Rezon Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Rezon Bio
↗Gdansk, Poland
Rezon Bio is a European biologics Contract Development and Manufacturing Organization (CDMO) established in 2025 following the demerger of Polpharma Biologics. The company specializes in end-to-end services for biopharma and biotech companies, covering cell line development, process development, and commercial-scale drug substance manufacturing.
Operating state-of-the-art facilities in Gdańsk and Warsaw-Duchnice, Poland, Rezon Bio leverages a strong heritage in biosimilars and innovative biologics development. The company is focused on providing cost-efficient, high-quality, and regulatory-compliant manufacturing solutions, with sites that have secured approvals from major global regulators including the FDA and EMA.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:2025
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO Service Provider)
Modalities:Mammalian cell culture, Microbial fermentation
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Biopharma and biotech companies requiring biologics manufacturing
COMPETITION
Position:Emerging
Competitors:Lonza, Samsung Biologics, Catalent, Boehringer Ingelheim BioXcellence
LEADERSHIP
Key Executives:
Adriana Kiędzierska-Mencfeld - CEO
Abdelkader Talha - VP Quality
LINKS
Website:rezonbio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Rezon Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.